Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Beam Therapeutics Inc. reported revenue of $140M, up 120.0% year over year. Operating margin was -274.6% and net margin -57.2%, on a free-cash-flow margin of -257.7% with capital expenditure at 10.7% of revenue. Every figure is computed directly from BEAM's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $140M | -274.6% | -57.2% |
| FY2024 | $64M | -654.3% | -593.1% |
| FY2023 | $378M | -46.7% | -35.1% |
| FY2022 | $61M | -555.6% | -474.5% |
| FY2021 | $52M | -757.0% | -714.9% |
How does BEAM compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.